If you have been reading about mitochondrial biogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
== Causes == Myxedema is known to occur in various forms of hypothyroidism, as well as hyperthyroidism, including Graves' disease. One of the hallmarks of Graves' disease is pretibial myxedema, myxedema of the lower limb. Myxedema is more common in women than in men. Myxedema can occur in:
A number of acute and chronic infections including Chlamydophila pneumoniae, influenza, Helicobacter pylori, and Porphyromonas gingivalis among others have been linked to atherosclerosis and myocardial infarction. Myocardial infarction can also occur as a late consequence of Kawasaki disease. Calcium deposits in the coronary arteries can be detected with CT scans. Calcium seen in coronary arteries can provide predictive information beyond that of classical risk factors. High blood levels of the amino acid homocysteine is associated with premature atherosclerosis; whether elevated homocysteine in the normal range is causal is controversial. In people without evident coronary artery disease, possible causes for the myocardial infarction are coronary spasm or coronary artery dissection.
=== The 2010s === For its 2010 and 2012 summer tours, the band was once again paired with Chicago, as it had been in 1974, 1999, and 2008. In 2010, Skylark resigned from the band after suffering a stroke. John Cowan, who had originally toured with the band in the mid-1990s, returned to take Skylark's place, and has been with the band ever since. Three months later, before the band embarked on its 2010 summer tour with Chicago, Hossack was forced to sit out following a diagnosis of cancer. Tony Pia, a member of the Brian Setzer Orchestra, was recruited to substitute for Hossack. Pia became an official touring member of the band following Hossack's death in 2012. The Doobie Brothers released their 13th studio album, World Gone Crazy, helmed by their longtime producer Ted Templeman, in 2010. World Gone Crazy was the first Doobie Brothers album Templeman produced since One Step Closer in 1980. The album's first single, "Nobody", was free-streamed on their website. By 2012, five members of the Doobie Brothers family were deceased: percussionist/vocalist LaKind in 1992, original bass guitarist / vocalist Shogren in 1999; saxophonist, keyboardist, vocalist, and flutist Bumpus in 2004, while en route to California for a solo tour; drummer and vocalist Knudsen in 2005, and drummer Hossack in 2012. The official documentary, Let the Music Play: The Story of the Doobie Brothers, was released in 2012. It features interviews and rare footage from their early days of the 1970s to the present day.
Through a process called melanogenesis, melanocytes produce melanin, which is a pigment found in the skin, eyes, hair, nasal cavity, and inner ear. This melanogenesis leads to a long-lasting pigmentation, which is in contrast to the pigmentation that originates from oxidation of already-existing melanin. There are both basal and activated levels of melanogenesis; in general, lighter-skinned people have low basal levels of melanogenesis. Exposure to UV-B radiation causes increased melanogenesis. The purpose of melanogenesis is to protect the hypodermis, the layer under the skin, from damage by UV radiation. The color of the melanin is black, allowing it to absorb a majority of the UV light and block it from passing through the epidermis. Since the action spectrum of sunburn and melanogenesis are virtually identical, they are assumed to be induced by the same mechanism. The agreement of the action spectrum with the absorption spectrum of DNA points towards the formation of cyclobutane pyrimidine dimers (CPDs) - direct DNA damage. Typically, between 1000 and 2000 melanocytes are found per square millimeter of skin or approximately 5% to 10% of the cells in the basal layer of epidermis. Although their size can vary, melanocytes are typically 7 μm in length.
Sources: en.wikipedia.org
== Structure == Mambalgins known to date consist of 57 amino acid residues and fold into a characteristic three-finger toxin (3FTx) structure. Two isoforms were originally described, called mambalgin-1 and mambalgin-2, which differ by a single amino acid residue. A third variant which differs by a single residue at another site, has subsequently been reported from venom profiling of the Eastern green mamba (Dendroaspis augusticeps). The X-ray structure of mambalgin-1 has been solved and consists of a three-finger protein fold with the typical three beta sheet-containing "finger" loops emanating from a central core stabilized by disulphide bonds; however, the structure differs from most 3FTx proteins in having an elongated second loop and shortened first and third loops. Mambalgins have relatively low sequence similarity to other 3FTx proteins and are most closely related to the 3FTx subclass known as the non-conventional or "weak" toxins. Human acid-sensing ion channel 1a inhibition (hASIC1aΔC) by snake toxin mambalgin1 develops a complex of three hASIC1aΔC subunits with six 6 NAG ligands (2 per subunit). The PDB code of this complex is 7CFT. Each hASIC1aΔC subunit is composed of an acid-sensing ion channel and a mambalgin1. Mambalgin1 is the toxin within hASIC1aΔC and is present in each subunit. The trimeric hASIC1aΔC shows a canonical chalice-like structure where each subunit of hASIC1aΔC harbors a cysteine-rich extracellular domain (ECD).
== Diagnosis == Penicillium expansum can be identified by its morphological characteristics and secondary metabolites in fruit, or in axenic culture. The presence of the secondary metabolite patulin can suggest P. expansum infection, but this method is not species-specific, as a number of different Penicillium species and their allies produce patulin. Patulin presence can be assayed using high-performance liquid chromatography with ultraviolet detection. Molecular methods based on species-specific genes can speed identification.
In the 2025 speculative fiction novel The Strange Case of Jane O. by Karen Thompson Walker, a New York City psychiatrist treats a hyperthymestic woman who has mysterious blackouts and hallucinations. In the 2025 romance novel The Survivor Wants to Die at the End by Adam Silvera, one of the protagonists, Alano Rosa, has hyperthymesia and can remember even before he was born. He relives every moment he remembers including feelings, which in some instances cause him physical pain.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.